Stock Financial Ratios, Dividends, Split History

SSP / Scripps Company financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)159.06
Enterprise Value ($M)718.56
Book Value / Share78.51
Price / Book0.17
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Shares Outstanding 11,932,722
Weighted Average Number Of Diluted Shares Outstanding 82,052,000
Common Shares Outstanding2 69,582,721
Weighted Average Number Of Shares Outstanding Basic 82,052,000
Preferred Stock Shares Outstanding 0
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.01
Return on Assets (ROA)-0.01
Return on Equity (ROE)-0.02
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio2.87
Income Statement (mra) ($M)
Other Sales Revenue Net40,414,000.00
Sales Revenue Net864,834,000.00
Retransmission And Carriage Revenue259,712,000.00
Advertising Revenue564,708,000.00
Operating Income-1.90
Net Income-14.62
Earnings Per Share Basic-0.16
Earnings Per Share Diluted-0.16
Cash Flow Statement (mra) ($M)
Cash From Operations40.85
Cash from Investing-299.07
Cash from Financing-299.07
Identifiers and Descriptors
Central Index Key (CIK)832428
Related CUSIPS
081105440 811054902 811054952

Split History

Stock splits are used by Scripps Company to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

Related News Stories

The E. W. Scripps' (SSP) CEO Adam Symson on Q1 2018 Results - Earnings Call Transcript

2018-05-07 seekingalpha
The E. W. Scripps Company (NYSE:SSP) Q1 2018 Earnings Conference Call May 7, 2018 9:00 AM ET (1-0)

CBS Corporation (CBS) Jumps: Stock Rises 9.1%

2018-05-07 zacks
CBS Corporation (CBS - Free Report) was a big mover last session, as the company saw its shares rise more than 9% on Friday. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $48.74 to $52.85 in the past one-month time frame. The move came after the company reported solid first-quarter 2018 results. (70-0)

CBS Q1 Earnings Beat Estimates, Non-Ad Revenues Grow Y/Y

2018-05-04 zacks
CBS Corporation (CBS - Free Report) delivered first-quarter 2018 adjusted earnings of $1.34 per share that beat the Zacks Consensus Estimate by 15 cents and jumped 28.8% from the year-ago quarter. Revenues increased 12.5% from the year-ago quarter to $3.76 billion and comfortably surpassed the consensus mark of $3.63 billion. Strong growth was driven by strong advertising (46.1% of revenues), content licensing & distribution (26. (66-0)

World Wrestling (WWE) Q1 Earnings Surpass, Revenues Miss

2018-05-04 zacks
World Wrestling Entertainment Inc. (WWE - Free Report) continued with its positive earnings surprise streak in 2018 as well. This integrated media and entertainment company posted first-quarter adjusted earnings of 18 cents a share that beat the Zacks Consensus Estimate of 13 cents, and surged considerably from 8 cents reported in the year-ago period. Clearly, the company’s effort to focus on increasing original content production, localization and strategic initiatives bode well. (16-0)

Should You Sell E. W. Scripps (SSP) Before Earnings?

2018-02-27 zacks
Investors are always looking for stocks that are poised to beat at earnings season and The E. W. Scripps Company (SSP - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. (47-0)

CUSIP: 811054402